Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Gynecologic Oncology

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2016.11.042PMID 27931750PMCID PMC7526046
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patterns of Care

  2020cited by this paper
• Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.

  2016cited by this paper
• Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

  2016cited by this paper
• Uterine carcinosarcoma: A review of the literature.

  2015cited by this paper
• Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis.

  2015cited by this paper
• Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.

  2014cited by this paper
• PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.

  2013cited by this paper
• Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas

  2013cited by this paper
• Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

  2013cited by this paper
• Contemporary management of endometrial cancer.

  2012cited by this paper
• Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.

  2012cited by this paper
• Uterine sarcomas: then and now.

  2012cited by this paper
• Prognostic Impact of the History of Breast Cancer and of Hormone Therapy in Uterine Carcinosarcoma

  2011influential reference
• Incidence and Survival Trends of Uncommon Corpus Uteri Malignancies in the Netherlands, 1989–2008

  2011cited by this paper
• Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

  2009cited by this paper
• Revised FIGO staging for carcinoma of the vulva

  2009cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?

  2005cited by this paper
• Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.

  2005cited by this paper
• Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer?

  2004cited by this paper
• Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

  2003influential reference
• IGF-1 in gynaecology and obstetrics: update 2002.

  2002cited by this paper
• Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of the literature

  2002cited by this paper
• Association of tamoxifen and uterine sarcoma.

  2002cited by this paper
• Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer

  2001cited by this paper
• Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases.

  2000cited by this paper
• Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.

  2000cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Activation of a Uterine Insulin-Like Growth Factor I Signaling Pathway by Clinical and Environmental

  2000cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

  1995cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper

• Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report

  2025cites this paper
• Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

  2025cites this paper
• Demographic features and prognostic factors of uterine carcinosarcoma: a study at a specialized center in Saudi Arabia

  2025cites this paper
• Presentación polipoide de un carcinosarcoma primario de vagina. Un caso clinicopatológico de esta neoplasia excepcional

  2024cites this paper
• Uterine carcinosarcoma: Unraveling the role of epithelial‐to‐mesenchymal transition in progression and therapeutic potential

  2024cites this paper
• Carcinosarcoma of uterus

  2023cites this paper
• HER2 amplification in Uterine carcinosarcoma after tamoxifen therapy: a case report

  2022cites this paper
• Survival for endometrial cancer as a second primary malignancy

  2022cites this paper
• Oncological Surgical Pathology

  2020cites this paper
• Secondary Sarcomas: Biology, Presentation, and Clinical Care.

  2020cites this paper
• Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma

  2019cites this paper
• Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators

  2019cites this paper
• Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis.

  2019cites this paper
• Tamoxifen in horses: pharmacokinetics and safety study

  2019cites this paper
• Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma.

  2019cites this paper
• Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery

  2018cites this paper
• Effects of Hormones

  2018cites this paper
• Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.

  2018cites this paper
• Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

  2018cites this paper
• Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma

  2018cites this paper
• Trends of uterine carcinosarcoma in the United States

  2018cites this paper
• Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.

  2017influential citation
• Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.

  2017cites this paper
• Significance of venous thromboembolism in women with uterine carcinosarcoma.

  2017cites this paper